Khiron Life Sciences closes bought deal financing

1 minute read
26 November 2020
Client work

Team:

Peter Simeon

On November 26, 2020, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, closed its previously announced "bought deal" short form prospectus offering of units, including the exercise in full of the over-allotment option.

A total of 32,200,000 units were sold for aggregate gross proceeds of $14,490,000 including the exercise in full of the over-allotment option. The offering was completed by a syndicate of underwriters led by Canaccord Genuity Corp., including ATB Capital Markets Inc. and Leede Jones Gable Inc.

Gowling WLG advised Khiron in this offering with a team that included Peter Simeon, Marek Lorenc, Stephen Franchetto and Howard Xi.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences, Cannabis, Capital Markets

Team

Related Insights & Resources

View all insights Related Insights & Resources
Client work
14 March 2024 Innocan Pharma closes non-brokered private placement
paperclip chain Articles
31 January 2024 Supply chain transparency reporting begins in Canada
Client work
05 January 2024 NurExone Biologic Inc. closes private placement financing

Team

Download or print PDF